Therefore, we suggest that clinicians pay attention to the occurrence of erectile dysfunction as a potential side effect of (prophylactic) antimigraine drugs which target CGRP or its receptor, namely gepants and monoclonal antibodies (including galcanezumab). The gene discussed is CALCA; the disease is erectile dysfunction.